Yuhan Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Yuhan wird ein jährliches Gewinn- und Umsatzwachstum von 24.1% bzw. 9.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 24% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.4% betragen.

Wichtige Informationen

20.2%

Wachstumsrate der Gewinne

19.3%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum36.9%
Wachstumsrate der Einnahmen9.6%
Zukünftige Eigenkapitalrendite9.3%
Analystenabdeckung

Good

Zuletzt aktualisiert25 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Estimating The Intrinsic Value Of Yuhan Corporation (KRX:000100)

Sep 16
Estimating The Intrinsic Value Of Yuhan Corporation (KRX:000100)

Subdued Growth No Barrier To Yuhan Corporation (KRX:000100) With Shares Advancing 41%

Aug 28
Subdued Growth No Barrier To Yuhan Corporation (KRX:000100) With Shares Advancing 41%

Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Jul 01
Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 13
Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

May 26
Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

May 13
Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Mar 11
Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

May 01
Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Apr 16
Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Mar 15
Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Feb 25
Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Feb 10
Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

Jan 28
Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

Jan 13
The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

Is Yuhan Corporation (KRX:000100) Popular Amongst Institutions?

Dec 31
Is Yuhan Corporation (KRX:000100) Popular Amongst Institutions?

Estimating The Fair Value Of Yuhan Corporation (KRX:000100)

Dec 18
Estimating The Fair Value Of Yuhan Corporation (KRX:000100)

Is Yuhan Corporation's (KRX:000100) 0.6% Dividend Worth Your Time?

Dec 05
Is Yuhan Corporation's (KRX:000100) 0.6% Dividend Worth Your Time?

Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Nov 20
Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Gewinn- und Umsatzwachstumsprognosen

KOSE:A000100 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (KRW Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20262,457,699238,356223,447269,95815
12/31/20252,299,098202,087185,760223,80016
12/31/20242,097,831159,540107,400172,03610
6/30/20241,893,119147,849-75,289100,417N/A
3/31/20241,860,529124,466-80,670110,014N/A
12/31/20231,858,984133,993-59,775144,128N/A
9/30/20231,872,33688,109-59,302113,301N/A
6/30/20231,820,81176,045-94,82448,972N/A
3/31/20231,808,041101,446-18,662106,905N/A
12/31/20221,775,84795,144-2,35699,529N/A
9/30/20221,749,31574,66921,500112,004N/A
6/30/20221,769,24597,83664,662146,027N/A
3/31/20221,719,63097,911-77,1461,983N/A
12/31/20211,687,810102,58317,72699,000N/A
9/30/20211,725,26198,128-40,21463,556N/A
6/30/20211,703,47597,833-90,02816,218N/A
3/31/20211,685,62397,57833,086125,628N/A
12/31/20201,619,865192,761-55,85428,830N/A
9/30/20201,552,188184,730-12,07640,572N/A
6/30/20201,504,765168,66795,017136,587N/A
3/31/20201,448,677140,227-32,34912,995N/A
12/31/20191,480,35440,00619,25165,985N/A
9/30/20191,500,78244,23022,26271,414N/A
6/30/20191,497,13041,438-43,9551,332N/A
3/31/20191,523,95452,333109,427156,727N/A
12/31/20181,518,82357,48145,60293,452N/A
9/30/20181,481,90670,14654,109108,573N/A
6/30/20181,482,03484,57248,987107,587N/A
3/31/20181,450,870100,288N/A112,160N/A
12/31/20171,462,248109,034N/A126,125N/A
9/30/20171,434,749139,325N/A116,234N/A
6/30/20171,417,835137,434N/A135,085N/A
3/31/20171,395,518139,440N/A142,224N/A
12/31/20161,320,797161,249N/A74,144N/A
9/30/20161,274,011134,997N/A98,827N/A
6/30/20161,223,925155,819N/A97,292N/A
3/31/20161,163,130152,682N/A88,684N/A
12/31/20151,128,731126,047N/A126,235N/A
9/30/20151,097,229118,104N/A120,389N/A
6/30/20151,046,71698,362N/A140,058N/A
3/31/20151,031,87594,628N/A71,402N/A
12/31/20141,017,49290,948N/A94,386N/A
9/30/20141,007,10995,434N/A78,642N/A
6/30/2014970,25387,696N/A44,515N/A
3/31/2014953,19183,863N/A56,486N/A
12/31/2013943,60986,461N/A79,778N/A
9/30/2013879,99785,032N/A86,196N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: A000100Das prognostizierte Gewinnwachstum (24.1% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: A000100Die Erträge des Unternehmens (24.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt KR (28.5% pro Jahr).

Hohe Wachstumserträge: A000100Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: A000100Die Einnahmen des Unternehmens (9.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt KR (10.5% pro Jahr).

Hohe Wachstumseinnahmen: A000100Die Einnahmen des Unternehmens (9.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: A000100Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.4%).


Wachstumsunternehmen entdecken